In conclusion, our study shows that the proposed visual scale of [18F]Florzolotau ([18F]APN1607) tau-PET is strongly associated with SUVr quantification and clinical diagnosis, suggesting that the visual scale of tau-PET is a robust and clinical application to distinguish AD with dementia patients from other older adults with cognitive decline. This evidence concerns the gene MAPT and Alzheimer disease.